10-K: Retractable Technologies Reports Fiscal Year 2023 Results Amidst Shifting Market Dynamics

Retractable Technologies, Inc. reports a decrease in revenue for fiscal year 2023, primarily due to reduced government sales and excess customer inventory, despite increased domestic unit sales in the latter part of the year.

Summary

• Retractable Technologies, Inc. reported a 54% decrease in overall revenue for fiscal year 2023, with a significant drop in both domestic and international sales.
• Domestic revenues decreased by 33.7% due to a lack of sales to the U.S. government, while international revenues fell by 78.9% due to reduced vaccination-related sales.
• Syringe sales accounted for 78.3% of total revenue, while EasyPoint products contributed 16.6%.
• The company experienced a net loss of $7.0 million, compared to a net income of $5.1 million in the previous year.
• Gross profit margins decreased from 29.8% in 2022 to 20.9% in 2023.
• Operating expenses decreased by 29.2%, primarily due to a $10.1 million stock option expense in 2022 that did not recur in 2023.
• The company's investment portfolio experienced an unrealized loss of $10.5 million, but a realized gain on sale of equity securities of $5.6 million.
• The company received an $8 million refund of previously paid state tax payments.
• The company reduced its workforce by approximately 22% in March 2023, resulting in annualized savings of approximately $1.7 million.
• The company's Chinese manufacturers produced approximately 88.4% of its products in 2023.
• The company has a Technology Investment Agreement (TIA) with the U.S. government, which was transferred to a successor agreement in April 2023, governing terms until June 30, 2030.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant revenue decline, net loss, and reduced profit margins. While there are some positives, such as cost-saving measures and increased domestic unit sales in the latter part of the year, the overall financial performance and market challenges weigh heavily on the sentiment.

Positives

• Domestic unit sales increased each quarter in 2023 for products associated with administering vaccinations, indicating a return to pre-pandemic seasonal trends.
• The company received an $8 million refund of previously paid state tax payments.
• The company reduced its workforce by 22% in March 2023, resulting in annualized savings of approximately $1.7 million.
• The company has a Technology Investment Agreement (TIA) with the U.S. government, which was transferred to a successor agreement in April 2023, governing terms until June 30, 2030.
• The company has access to its investments which may be liquidated in the event that it needs to access the funds for operations.

Negatives

• Overall revenue decreased by 54% year-over-year.
• The company reported a net loss of $7.0 million for 2023.
• Gross profit margins decreased from 29.8% in 2022 to 20.9% in 2023.
• The company experienced an unrealized loss of $10.5 million on debt and equity securities.
• Domestic revenues decreased 33.7% due to the lack of sales to the U.S. government.
• International revenues decreased 78.9% due to fewer international vaccination-related sales.
• The company believes domestic customers have retained products provided for vaccination purposes in inventory, leading to a decrease in demand.

Risks

• The company's stock price is not correlated with its value, with a market capitalization of $33.2 million and total stockholders equity of $99.3 million as of December 29, 2023.
• Customers have excess product inventory, leading to decreased demand.
• The company is vulnerable to the expiration of patents on its VanishPoint syringes, which could lead to a significant loss of sales.
• The company faces competition from larger companies with greater resources, such as Embecta Corp.
• The company relies heavily on Chinese manufacturers, with 88.4% of products sourced from China in 2023, creating supply chain risks.
• The company is controlled by one shareholder, Thomas J. Shaw, who has significant influence over operations and financial affairs.
• The company is subject to product liability risks, as evidenced by a voluntary recall of EasyPoint needles in February 2024.
• The company's investment portfolio is subject to market risk, with 19.3% of total assets invested in the market.
• Health crises could disrupt operations and supply chains.
• Cybersecurity threats could harm the company's business, customer relations, and financial condition.
• Illegal distribution and sale of counterfeit products could negatively impact the company's reputation and business.

Future Outlook

The company believes it has adequate means to meet short-term needs to fund operations for at least 12 months. The company may fund operations from revenues, cash reserves, and investments available for sale if needed. The company expects domestic demand to remain depressed until excess inventory is depleted, but domestic unit sales have increased each quarter of 2023.

Management Comments

• Management believes that domestic customers have retained products provided for vaccination purposes in inventory, leading to a decrease in demand.
• Management is responsible for directing investment activity based on current economic conditions.
• Management believes the institutions holding cash balances are of high credit quality.
• Management considers any exposure from concentrations of credit risks to be limited.
• Management believes that it has sufficient historical data, and a firm basis for establishing reserves for contractual obligations.

Industry Context

The company operates in the competitive medical device industry, facing challenges from larger, more established companies. The COVID-19 pandemic significantly impacted the company's sales, with a surge in government orders followed by a decline as vaccination efforts slowed. The company is adapting to changing market dynamics, including shifts in domestic and international demand, and is focusing on its core safety medical products.

Comparison to Industry Standards

• Retractable Technologies faces strong competition from Becton, Dickinson and Company (BD) and its spin-off, Embecta Corp., which have significantly greater resources and market share.
• Embecta, with 2,200 employees, contrasts sharply with Retractable Technologies' less than 200 employees, highlighting the resource disparity.
• The company's reliance on Chinese manufacturers for 88.4% of its products in 2023 is a common practice in the medical device industry, but it also exposes the company to supply chain risks.
• The company's focus on safety features, such as retractable needles and low dead space syringes, aligns with industry trends emphasizing healthcare worker and patient safety.
• The company's gross profit margin of 20.9% in 2023 is lower than the 29.8% in 2022, indicating a potential challenge in maintaining profitability compared to industry benchmarks.
• The company's net loss of $7.0 million in 2023 contrasts with its net income of $5.1 million in 2022, suggesting a significant downturn in financial performance compared to previous years.

Corporate Governance

Legal Proceedings

• The company has a lawsuit against Locke Lord, LLP and Roy Hardin in connection with their legal representation of the company in its previous litigation against Becton, Dickinson and Company.
• The case is currently not set for trial, and a hearing on a Motion for Summary Judgment is set for April 9, 2024.

Related Party Transactions

• The company has a license agreement with its Chief Executive Officer, Thomas J. Shaw.
• The company repurchased three million shares of stock from BML Investment Partners, L.P., a 10% stockholder at the time of the transaction.

Stakeholder Impact

• Shareholders may be concerned about the company's decreased revenue, net loss, and reduced profit margins.
• Employees may be affected by the workforce reduction and potential future cost-saving measures.
• Customers may be impacted by the product recall and potential supply chain disruptions.
• Suppliers may be affected by changes in the company's manufacturing and sourcing strategies.
• Creditors may be concerned about the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to evaluate the appropriate mix of products manufactured domestically and those manufactured in China.
• The company will continue to comply with applicable regulations of all countries in which its products are registered for sale.
• The company will continue to evaluate current compensation rates and job descriptions with industry standard salary surveys to maintain competitive wages.
• The company will continue to work with customers and distributors to determine how many of the units remain unused and subject to the EasyPoint Needle recall.
• The company will continue to work with the U.S. Food and Drug Administration in connection with the EasyPoint Needle recall.

Key Dates

Keywords

safety medical products, syringes, VanishPoint, EasyPoint, COVID-19, vaccination, intellectual property, manufacturing, government contracts, international sales, supply chain, financial results